Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data Cardiff Oncology, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
0.38
0.51
0.38
0.24
0.37
0.36
0.39
0.49
0.68
0.59
Cost of revenue
1.73
1.81
0.6
0
Gross profit
-1.35
-1.31
-0.22
0.24
Research and development
15
7.88
8.16
11.2
11.2
17.4
27.1
32.9
36.9
35.3
Selling, general and administrative
14.2
8.01
5.76
8.22
11.8
13.2
13
12.5
14.2
Selling and marketing
11.5
2.74
General and administrative
11.5
11.5
Operating expenses
40.5
26.1
17.4
16.9
19.5
29.2
40.3
45.9
49.3
49.6
Operating income
-40.1
-25.6
-17.1
-16.7
-19.1
-28.9
-39.9
-45.4
-48.7
-49
Interest expense
1.67
1.03
0.03
0
0
0
Interest income
0.3
0.15
0.22
0.23
0.09
0.26
1.58
4.07
3.26
3.1
Other non-operating income
-0.22
0.56
1.2
3.97
3.22
3.11
Pre-tax income
-45.4
-45.9
Income tax
0
0
0
0
0
0
0
0
0
0
Net income
-39.2
-24.9
-16.5
-16.4
-19.3
-28.3
-38.7
-41.4
-45.4
-45.9
EBITDA
-39.1
-24.3
-16.2
-16.2
-18.6
-28.4
-39.7
-45
-48.2
-48.6
EPS, basic
-93.46
-51.76
-8.26
-2.80
-1.08
-0.73
-0.89
-0.93
-0.95
-0.69
EPS, diluted
-98.49
-51.76
-8.26
-2.80
-1.08
-0.73
-0.89
-0.93
-0.95
-0.69
Shares, basic (weighted)
0.42
0.48
2.33
5.97
20.9
39
43.6
44.7
47.7
66.8
Shares, diluted (weighted)
0.42
0.48
2.33
5.97
20.9
39
43.6
44.7
47.7
66.8
Balance sheet
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
13.9
8.23
11.5
10.2
131
11.9
16.3
21.7
51.5
17.5
Short-term investments
24
0
0
129
88.9
53.2
40.3
40.8
Receivables
0.1
0.08
0.17
0.2
0.32
0.54
0.77
0.29
0.77
0.18
Other current assets
0.96
1.17
1.14
0.95
2.06
4.77
5.25
2.3
2.54
1.64
Total current assets
39
9.47
12.8
11.4
133
146
111
77.4
95.1
60.1
Property, plant and equipment
3.83
2.43
1.3
0.88
0.62
0.38
1.27
1.24
0.9
0.58
Lease right-of-use assets
0
0.7
0.34
2.8
2.25
1.71
1.17
0.63
Long-term investments
33.3
5
26.9
6.27
8.89
Other non-current assets
1.17
0.39
0.1
0.16
0.4
0.24
1.39
1.28
0.07
0.55
Total assets
44
12.3
14.2
13.1
135
150
116
81.6
97.2
61.9
Accounts payable
1.13
0.83
0.66
0.66
1.37
1.44
1.96
1.97
4.82
8.09
Accrued liabilities
4.02
1.45
1.77
3.26
3.85
4.53
5.18
7.78
7.9
7.58
Short-term debt
2.36
1.33
0
Total current liabilities
7.8
3.95
2.92
4.78
6.12
6.56
7.81
10.4
13.4
16.4
Long-term debt
14.2
0
0
Lease liabilities
0
0.86
0.01
2.57
2.04
1.46
0.81
0.1
Other non-current liabilities
0.04
0.13
0.16
0
Total liabilities
24.2
5.78
4.09
5.78
6.57
9.13
9.85
11.9
14.2
16.5
Total debt
16.5
1.33
0
Paid-in capital
168
180
202
217
362
401
405
409
467
475
Retained earnings
-148
-173
-192
-209
-231
-260
-298
-340
-384
-430
Other comprehensive income
-0.01
0
0
-0.14
-0.4
-0.07
0.03
0.05
Shareholders' equity
19.8
6.51
10.1
7.31
128
140
106
69.7
82.9
45.4
Total equity
19.8
6.51
10.1
7.31
128
140
106
69.7
82.9
45.4
Total liabilities and equity
44
12.3
14.2
13.1
135
150
116
81.6
97.2
61.9
Shares outstanding
0.43
0.73
3.83
8.59
36.8
42
44.7
44.7
66.5
68.3
Cash flow statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-39.2
-24.9
-16.5
-16.4
-19.3
-28.3
-38.7
-41.4
-45.4
-45.9
Depreciation and amortization
1.07
1.25
0.86
0.49
0.47
0.45
0.24
0.4
0.4
0.36
Stock-based compensation
7.5
4.01
2.17
0.88
1.77
3.23
4.26
4.51
4.76
5.69
Deferred income tax
-16.6
13
-3.74
-2.78
-4.14
-6.08
24
-9.09
-9.26
-8.83
Change in receivables
-0
0.02
0.02
-0.04
-0.12
-0.22
-0.24
0.48
-0.48
0.59
Change in payables
2.16
-2.94
0.21
1.46
1.28
0.72
1.35
2.83
2.99
2.2
Cash from operations
-31
-23.3
-13.2
-13.3
-16.3
-23
-33.8
-30.9
-37.7
-37.9
Capital expenditures
-0.82
-0.1
-0.01
-0.07
-0.21
-0.21
-1.01
-0.58
-0.08
-0.04
Purchases of investments
0
-174
-91.2
-70.1
-23.6
-71.9
Sales and maturities of investments
0
28.4
76.4
86.6
27.1
71.1
Cash from investing
-24.8
24
0.02
-0.07
-0.21
-131
38.1
36.2
13.7
1.34
Debt issued
7.81
0
0
0.31
0
Debt repaid
-8.9
-15
0
Stock issued
2.36
11.7
11.8
8.82
112
34.2
0
0
53.4
0
Cash from financing
2.3
-6.38
16.4
12.1
137
35.5
0.08
0
53.8
2.58
Exchange rate effect
-0.01
0.01
0
Net change in cash
3.23
-1.26
121
-119
4.4
5.31
29.8
-34
Free cash flow
-31.9
-23.4
-13.2
-13.3
-16.5
-23.2
-34.8
-31.5
-37.8
-38
Interest paid
1.1
0.67
0.02
0
Income taxes paid
0
0
0
0
0
0
0
0
0
0
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $1.24 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Operating margin
-8,320.0%
Operating income / revenue.
EBITDA margin
-8,251.0%
EBITDA (operating income + depreciation and amortization) / revenue.
Net margin
-7,884.0%
Net income / revenue.
Operating cash flow margin
-8,042.0%
Cash from operations / revenue.
Return on equity (ROE)
-151.0%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-107.3%
Net income / average total assets.
Return on invested capital (ROIC)
-192.6%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue
5,109.0%
Research and development expense / revenue.
SG&A / revenue
3,311.0%
Selling, general and administrative expense / revenue.
Stock-based pay / revenue
1,029.0%
Stock-based compensation (from the cash flow statement) / revenue.
D&A / revenue
69.1%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
-13.2%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
15.4%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
10.1%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value growth, 1y
-45.3%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
-24.7%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
-18.7%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
-36.3%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-18.9%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-14.4%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
40.3%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
15.3%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
26.2%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
3.30x
Current assets / current liabilities.
Quick ratio
3.21x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
3.20x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$0.01
Revenue / diluted weighted shares.
Operating cash flow per share
-$0.60
Cash from operations / diluted weighted shares.
Book value per share
$0.39
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
190x
Market cap / revenue.
P/B
3.64x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
3.64x
Market cap / tangible book value, when positive.
EV/Sales
122x
Enterprise value / revenue.
Earnings yield
-41.5%
Net income / market cap (the inverse of P/E).
What was Cardiff Oncology, Inc.'s revenue in fiscal 2025?
Cardiff Oncology, Inc. reported revenue of $593.0K for fiscal 2025, 13.2% lower than the year before.
Was Cardiff Oncology, Inc. profitable in fiscal 2025?
No. It reported a net loss of $45.9M.
How much free cash flow did Cardiff Oncology, Inc. generate in fiscal 2025?
Cash from operations of $37.9M minus capital expenditures of $44.0K left free cash flow of -$38.0M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.